"We are delighted to welcome Pär Ihrskog to the Vitrolife Group as CFO. His extensive financial expertise, combined with a proven track record of leadership in listed companies, brings valuable ...

Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS) ...

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) (the “Company”) provides an update on its operational situation ...

About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in ...

About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...

About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center ...

Produced biologically using bacteria, these "natural soaps" are a more environmentally friendly, less irritating and ...

Oxurion received a transparency notification on April 1, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 31, 2025, it held 925,088 shares of the then outstanding 4,634,663 ...

28 March 2024, Leuven, Belgium — Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report 'seeding' this accumulation ...

Researchers have developed a laboratory model that mimics the pathological aggregation of TDP-43, a key protein in ALS and ...